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In 1796, English physician Edward Jenner introduced the rst vaccine, for smallpox, when he infected a young boy with cowpox. In the years since, vaccines -a name derived from the Latin word for cow -have been developed for many diseases, saving millions of lives. But the ght to conquer infectious disease continues.
By Neil Savage; infographic by Alisdair Macdonald 3. APCs move to where immune cells cluster. They activate T helper cells, which trigger activity in killer T cells (4a) and the maturation of B cells (4b).
4a. Naive killer T cells become active killer T cells specific to the antigen.
5a. If the vaccine contains a live attenuated virus that infects cells, killer T cells will then target and destroy those cells.
DNA vaccine
DNA from pathogens, sometimes attached to another virus or bacterium, is used to generate an immune response.
In human trials for herpesvirus, influenza and Zika virus.

Recombinant vector vaccine
Live but harmless viruses are genetically engineered to express an antigen to a dangerous virus, which the immune system can target.
Being explored for Zika virus, HIV and Ebola.
4b. Naive B cells, activated either by T helper cells or directly by antigens, become plasma B cells specific to the antigen. 5b. Plasma B cells produce antibodies that bind to antigens, preventing them from entering cells and marking them for destruction by killer T cells.
Subunit vaccine Live, attenuated vaccine
Toxoid vaccine
IN DEVELOPMENT
Memory cells
If the vaccinated person encounters the pathogen again, memory cells enable the body to mount a faster, stronger defence. 
VACCINE VARIETIES
There are several types of vaccine in use, each with their own strengths and weaknesses. Many are administered along with adjuvants -substances such as aluminium salts, lipids and RNA that strengthen the immune response.
IMMUNE STIMULATION
Vaccines can be administered orally, nasally or by injection: into the muscle mass, into the layer between skin and muscle or into the outer layer of skin. They stimulate an immune response that gives the body the ability to mount a swifter defence to the same pathogen if it is encountered again.
2.
Antigen-presenting cells (APCs) capture and ingest the antigen, then display pieces of it on their surfaces.
1. Antigens, often in the form of molecules on the surface of viruses or bacteria, are introduced into the bloodstream.
Inactivated vaccine
The pathogen is treated with heat or chemicals to kill it before it is introduced into the body. 
SAVING LIVES
Case numbers of certain infectious diseases in the United States dropped precipitously after e ective vaccines for each were widely adopted.
BUILDING COVERAGE
Vaccines initially developed in the 1950s and 1960s, such as those for polio and measles, are commonly administered globally. Those introduced more recently, such as that for rotavirus, are less widely used.
LONG ROAD TO NEW VACCINES
Development programmes are under way for a number of deadly diseases that currently lack a vaccine. In many cases, the pathogen responsible was identified decades ago, but e ective vaccination strategies have proved elusive.
Reported US cases (thousands)
The WHO recommends two doses of measles vaccine, but 23 of its 194 member states require only one dose. 
THE LUXURY OF HESITANCY
Although 79% of people globally think that vaccines are safe, trust varies widely between nations. Europe has some of the lowest levels of perceived safety -a finding that might partly explain the surge in measles cases seen in Ukraine in 2018. But other factors besides hesitancy to vaccinate also a ect the spread of infections.
In 2016, only 31% of 6-year-olds had received a second measles jab in Ukraine.
France experienced a 462% increase in measles cases between 2017 and 2018. 
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